

| OMB APPROVAL | |
|--|-----------|
| OMB Number: | 3235-0287 |
| Estimated average burden hours per response: | 0.5 |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | | | | | | |
|---|--|--|---|--|--|---|--|--|
| 1. Name and Address of Reporting Person* <u>PACE GARY W</u> _____ (Last) (First) (Middle) <u>C/O PACIRA BIOSCIENCES, INC.</u> <u>5 SYLVAN WAY, SUITE 300</u> _____ (Street) <u>PARSIPPANY NJ 07054</u> _____ (City) (State) (Zip) | | | 2. Issuer Name and Ticker or Trading Symbol <u>Pacira BioSciences, Inc. [PCRX]</u> | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below) | | |
| | | | 3. Date of Earliest Transaction (Month/Day/Year) <u>03/12/2020</u> | | | | | |
| | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|---------|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price | | | |
| Common Stock | 03/12/2020 | | M | | 4,649 | A | \$1.61 | 41,602 | D | |
| Common Stock | 03/12/2020 | | M | | 4,649 | A | \$1.61 | 46,251 | D | |
| Common Stock | 03/12/2020 | | M | | 7,438 | A | \$1.61 | 53,689 | D | |
| Common Stock | 03/12/2020 | | M | | 5,000 | A | \$13.98 | 58,689 | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
|--|--|--------------------------------------|--|--------------------------------|---|--|-------|--|-----------------|---|--|--|---|--|-------|
| | | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | | | | | | Title |
| Stock Option (Right to Buy) | \$1.61 | 03/12/2020 | | M | | | 4,649 | (1) | 09/02/2020 | Common Stock | 4,649 | \$0.00 | 0 | D | |
| Stock Option (Right to Buy) | \$1.61 | 03/12/2020 | | M | | | 4,649 | (2) | 09/02/2020 | Common Stock | 4,649 | \$0.00 | 0 | D | |
| Stock Option (Right to Buy) | \$1.61 | 03/12/2020 | | M | | | 7,438 | (3) | 09/02/2020 | Common Stock | 7,438 | \$0.00 | 0 | D | |
| Stock Option (Right to Buy) | \$13.98 | 03/12/2020 | | M | | | 5,000 | (4) | 06/02/2021 | Common Stock | 5,000 | \$0.00 | 0 | D | |

Explanation of Responses:

- The option vested as to 25% of the option shares on September 2, 2011 and, as to the remaining shares, in successive equal monthly installments for the subsequent 36 months. The option shares became exercisable, to the extent vested, from and after the issuer's initial public offering.
- The option vested as to 50% of the option shares upon the first anniversary of the issuer's initial public offering and, as to the remaining 50% of the option shares, upon the second anniversary of the issuer's initial public offering. The option shares became exercisable, to the extent vested, from and after the issuer's initial public offering.
- The option vested as to 50% of the option shares on September 2, 2010 and, as to the remaining 50% of the option shares, in successive equal monthly installments for the subsequent 24 months. The option shares became exercisable, to the extent vested, from and after the issuer's initial public offering.
- The option vested in 12 equal monthly installments beginning on July 2, 2011.

Remarks:

/s/ Kristen Williams, Attorney-in-Fact 03/16/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.